ClinicalTrials.gg
CompletedNCT04347499Updated Nov 8, 2022

Culturally Adapted CBT Based Guided Self-Help in Patients With Postnatal Depression

An interventional study of CaCBT based guided self help using Khushi aur Khatoon Manual in Postnatal Depression, sponsored by Peshawar Medical College. Completed at 1 site in Pakistan. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2022-11-08.

Sponsored by Peshawar Medical College · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Aug 2019, registered Apr 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Depression, Postpartum with a site in Pakistan — 2 open to participants now, 2 under way, none of them phase 3. Depression, Postpartum · Pakistan.

Enrollment
5th of 12
140 · median 107
Started
2019
with 1 other
No phase
10 of 12
2 open now
Registered
5th of 12
by date
Lead sponsor
1 of 12
Peshawar Medical College

Among the 12 studies in Depression, Postpartum with a site in Pakistan, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 10 with no phase, and was the 5th registered.

Depression, Postpartum

570 studies on the registry are indexed under Depression, Postpartum; 135 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

2 of the 12 studies in Depression, Postpartum with a site in Pakistan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 88 Depression, Postpartum studies recruiting now, 54 (61%) set no upper age limit and 31 (35%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Depression, Postpartum with a site in Pakistan, or all of them as a file.
02

Study summary

This is a randomized controlled assessor-blind clinical trial comparing CaCBT based guided self-help (using a manual titled Khushi Aur Khatoon) against treatment as usual (TAU)

Read the detailed description

The prevalence of postnatal depression(PND) in Asian countries ranges from 3.5% to 63.3% where Malaysia and Pakistan have the lowest and highest, respectively. Risk factors for postnatal depression have been clustered into biological/ physical (e.g., Vitamin B Deficiency), psychological (e.g., antenatal depression), obstetric/pediatric (e.g., unwanted pregnancy), socio-demographic (e.g., poverty), and cultural factors (e.g., preference of infants' gender).

Cognitive behaviour therapy (CBT) is the best-studied form of psychotherapy in patients who have had Postnatal Depression, in reducing depressive symptoms. This study is planned to explore the effect of culturally adapted Cognitive Behaviour Therapy (CaCBT) based Guided self-help (using the book, Khushi Aur Khatoon) compared with treatment as usual in improving depression in PND patients. Participants visiting a tertiary care hospital in Karachi, who meet the entry criteria will be randomly allocated to one of the groups, i.e., CaCBT (Intervention group) or TAU (Control Group) in a 1:1 ratio. after taking written informed consent.

The sample size calculation is based on the assumption of using an Analysis of Covariance (ANCOVA) to analyze the outcome while controlling for baseline and is based on formulas given by Van Breukelen GJP and Borm GF et al. The investigators assume a correlation between baseline EPDS and endpoint EPDS of 0.5, 90% power, and a significance level of 0.05 with the two-sided test. A sample of 48 subjects per group is sufficient to achieve the expected power to detect an effect size equivalent to Cohen's d=0.3, which is a small to medium effect size. Considering means and standard deviations, this effect is equivalent to a difference of 0.8 points at the post, between the groups, in average EPDS score. To accommodate for up to 30% of dropouts, the investigators plan to recruit 140 participants in the study.

Participants were assessed at baseline and 9-12 weeks (end of therapy) from baseline. The primary outcome measure was the Edinburgh Postnatal Depression Scale (EPDS). The secondary outcome measures include Bradford Somatic Inventory (BSI) and World Health Organization Disability Assessment Schedule (WHO DAS 2.0). The investigators also measured satisfaction with the treatment at the end of therapy using a visual analog scale from the intervention group.

The investigators followed the CONSORT guidelines for reporting randomized controlled trials. The analyses were carried out on an intention-to-treat basis using SPSS version 25. Comparisons for intention-to-treat analysis participants were included in the groups to which they are randomized regardless of how long or even whether they received the treatment allocated to them or not. Missing values were imputed using the last observation carried forward (LOCF) method. Both Chi-Square and t-tests were used for baseline comparisons. End-of-therapy scores on various outcome measures between the Intervention and the Control groups were compared using an Analysis of Covariance (ANCOVA) to adjust for baseline scores.

03

Conditions studied

  • Postnatal Depression

Keywords

  • Cognitive Behaviour Therapy
  • Postnatal Depression
  • Guided Self Help
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Score of 10 or more on EPDS
  • Fulfilling criteria of Major Depressive Disorder using with a specifier of Peripartum Onset.

Exclusion criteria

Exclusion Criteria:

  • Participants with use of alcohol or drugs
  • Significant cognitive impairment (intellectual disability or dementia)
  • Active psychosis
  • Participants who have received CBT during the previous 12 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    Intervention

    This group will receive CaCBT based guided selfhelp using the manual (Khushi Aur Khatoon) as an intervention in addition to treatment as usual

    Other: CaCBT based guided self help using Khushi aur Khatoon Manual

  • No intervention
    Control

    This group will receive treatment as usual

Interventions

  • OtherCaCBT based guided self help using Khushi aur Khatoon Manual

    CaCBT based guided self help using the manual named Khushi Aur Khatoon in the intervention arm

06

What researchers measure

Primary outcomes

  1. Edinburgh Postnatal Depression Scale (EPDS)

    Change in the score of Edinburgh Postnatal Depression (EPDS) from baseline to end of therapy Minimum Score = 0 Maximum Score = 30 Scores are between 0 and 30, with scores 13 and above indicating depressive illness, or a high risk of developing a depressive disorder. Higher scores means a worse outcome.

    Time frame: 9-12 weeks (end of therapy)

Secondary outcomes

  1. Bradford Somatic Inventory (BSI)

    Change in the score of Bradford Somatic Inventory (BSI) from baseline to end of therapy Minimum Score = 0 Maximum Score = 92 Higher scores mean a worse outcome.

    Time frame: 9-12 weeks (end of therapy)

  2. World Health Organisation Disability Assessment Schedule (WHODAS 2.0)

    Change in the score of World Health Organisation Disability Assessment Schedule (WHODAS 2.0) from baseline to end of therapy Minimum Score = 0 Maximum Score = 48 Higher scores mean a worse outcome.

    Time frame: 9-12 weeks (end of therapy)

07

Study locations

1 site
  • Zainab Panjwani Hospital
    Karachi, Pakistan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Feb 2020, 5 months.

Of 259 non-industry interventional studies with no phase under Depression, Postpartum, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 5 months is below that.

Counting every sponsor, half of 265 studies reached it within 23 months; a quarter within 11 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2020
First posted
Apr 15, 2020
StartActual
Aug 5, 2019
Primary completionActual
Feb 2, 2020
CompletionActual
Nov 1, 2020
Last update
Nov 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04347499
Lead sponsor
Peshawar Medical College
Collaborators
Pakistan Association of Cognitive Therapists
Responsible party
Muhammad Irfan (Prof. of Psychiatry & Director Research, Peshawar Medical College) — Principal investigator
First posted
Apr 15, 2020
Start date
Aug 5, 2019
Primary completion
Feb 2, 2020
Completion
Nov 1, 2020
Last update
Nov 8, 2022

Study contacts

Farooq Naeem, PhD
study chair · University of Toronto

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion